One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1671 articles with Amgen
For investors looking for a big pharma stock, AbbVie and Pfizer are both top choices.
Amgen(NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab).
5/18/2018Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab)
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s Epogen/Procrit (epoetin alfa). The drugs treat anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in HIV patients.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Preclinical findings were discussed in poster presentations at the recent American Association for Cancer Research (AACR) Annual Meeting.
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018. David W. Meline, executive vice president and chief financial officer at Amgen, and David M. Reese, senior vice president of Translational Sciences and Oncology at Amgen, will present at the conference
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
Artificial body parts have been around for some time. Patients have access to artificial limbs, hearts, eyes, skin and more thanks to the innovation of biomedical engineers. As technology improves, so do the advancements in these man-made devices.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
Janssen Strikes Deal to Acquire BeneVir and its Oncolytic Virus Platform in Deal Worth Up to $1 B...
5/2/2018Shares of HC2 Holdings, Inc. skyrocketed more than 51 percent in premarket trading today after Janssen Biotech Inc announced it was acquiring Rockville, Maryland-based BeneVir Biopharm, Inc., a subsidiary of HC2 in a deal that could be worth more than $1 billion.
Sanofi and Regeneron made a deal with pharmacy benefits manager Express Scripts for their Praluent, making it the exclusive PCSK9 inhibitor on their national formulary, essentially locking Amgen’s Repatha out of that market segment.
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Treats Bone Loss in Patients Using Glucocorticoid Medications who are at Increased Risk of Fracture
Amgen’s New Products Deliver Double-Digit Growth While Facing Down Pricing Pressure for New Migra...
4/25/2018In its first-quarter earnings report, Thousand Oaks, California-based Amgen cited total revenue for the quarter of $5.6 billion, up 2 percent compared to the first quarter of 2017. But the quarter’s earnings were driven by double-digit growth for new and recently launched products.